These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21329229)

  • 1. Renal protection in diabetes.
    Hunter JD; Ravert PK; Lassetter JH; Williams M
    Adv NPs PAs; 2011 Jan; 2(1):25-9; quiz 30. PubMed ID: 21329229
    [No Abstract]   [Full Text] [Related]  

  • 2. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?
    Onuigbo MA
    Int J Clin Pract; 2010 Sep; 64(10):1341-6. PubMed ID: 20716141
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lessons from the novel renoprotective studies with antihypertensive drugs].
    Bajnok L
    Orv Hetil; 2013 Feb; 154(7):243-7. PubMed ID: 23395787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
    Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
    Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Normoalbuminuria at all costs?].
    Maggio M
    G Ital Nefrol; 2011; 28(4):354. PubMed ID: 21809300
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE inhibitor use and the long-term risk of renal failure in diabetics.
    Woo KT; Lau YK; Wong KS; Chan CM
    Kidney Int; 2006 Oct; 70(7):1376-7; author reply 1378. PubMed ID: 16988741
    [No Abstract]   [Full Text] [Related]  

  • 10. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Choice of drug in hypertension].
    Schultz M; Aksnes TA; Høieggen A; Kjeldsen SE
    Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1802-3. PubMed ID: 24042290
    [No Abstract]   [Full Text] [Related]  

  • 12. Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus.
    Parving HH
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):30-1. PubMed ID: 11967794
    [No Abstract]   [Full Text] [Related]  

  • 13. Normalization of kidney dysfunction in normotensive, normo-albuminuric type 2 diabetes.
    Futrakul N; Futrakul P
    Ren Fail; 2013 Aug; 35(7):1058-9. PubMed ID: 23859540
    [No Abstract]   [Full Text] [Related]  

  • 14. In brief: aliskiren trial terminated.
    Med Lett Drugs Ther; 2012 Jan; 54(1382):5. PubMed ID: 22267213
    [No Abstract]   [Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S; Aurell M
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the renin-angiotensin system: added value in reducing cardiovascular and renal risk?
    Marshall SM
    Diabet Med; 2004 Jan; 21(1):1-3. PubMed ID: 14706047
    [No Abstract]   [Full Text] [Related]  

  • 17. Renoprotection with antihypertensive agents.
    Hilgers KF; Mann JF
    Lancet; 2002 May; 359(9318):1693; author reply 1693-4. PubMed ID: 12020551
    [No Abstract]   [Full Text] [Related]  

  • 18. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract]   [Full Text] [Related]  

  • 19. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.